权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pediatric Mendelian Genomics Research Center

儿科孟德尔基因组学研究中心

基本信息

批准号：
10415121
负责人：
Eric J. Vilain
金额：
$ 255.9万
依托单位：
CHILDREN'S RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-01 至 2022-10-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10415121
关键词：
Address Affect Alleles Basic Science Benign Candidate Disease Gene Child Childhood Classification ClinVar Clinical Clinical Research Code Collaborations Consanguinity Copy Number Polymorphism Data Data Coordinating Center Diagnosis Disease Disease Management Enrollment Ensure Evaluation Family Family member Genes Genetic Genetic Counseling Genomics Goals Health Personnel Healthcare Systems Hospitals Individual Investigation Mendelian disorder Methods Modeling Molecular Optics Pathogenicity Patients Phenotype Population Population Heterogeneity Process Proxy Public Health Publications Publishing RNA Splicing Rare Diseases Reproducibility Research Research Institute Sampling Source Standardization Structure Syndrome System Taxes Technology Testing Tissues Translating Translational Research Untranslated RNA Variant burden of illness clinical implementation clinical practice cohort community center data dissemination data sharing diagnostic strategy disease phenotype exome sequencing gene discovery genetic testing genetic variant genome-wide genomic data improved industry partner innovation mRNA Expression novel patient registry public database recruit repository symposium transcriptome transcriptome sequencing variant of unknown significance whole genome

项目摘要

ABSTRACT Mendelian conditions, particularly those presenting during childhood, are a major disease burden causing suffering and taxing the healthcare system. Clinical approaches including exome sequencing have led to a rapid increase in the number of conditions with known genetic causes and new treatment options for many rare diseases, but are restricted to finding small coding and splice junction variants, missing most non-coding variants as well as structural and copy number variants. This challenges interpretation due to the vast number of variants that must be analyzed for possibly causing a disease. To accelerate the pace of Mendelian disease gene discovery and clinical implementation, we propose a Pediatric Mendelian Genomics Research Center (MGRC), leveraging the broad pediatric clinical and research expertise of Children’s National Hospital and Research Institute in a partnership with Invitae’s expertise in providing comprehensive and affordable genetic testing. Our Center will unite world class experts combining basic and translational research with innovative approaches to phenotyping, variant identification and functional investigation of both coding and non-coding sequence changes with the goals of discovering novel Mendelian gene variations and identifying variants not detected on current sequencing pipelines, disambiguating uncertain variants into disease-causing versus benign categorizations, and sharing information by working collaboratively with the MGRC community. To answer these challenges, this proposal will address the following Specific Aims: Aim 1: Identify novel causes of Mendelian conditions - Discover: Our center will enroll patients with likely Mendelian diseases and previously non-diagnostic tests (2,600 samples per year) then systematically re- analyze whole genomes augmented with long read sequencing, optical mapping, and RNA-seq. Aim 2: Reclassify uncertain variants and investigate the mechanisms of undiagnosed Mendelian conditions - Disambiguate: Uncertain variants and candidate genes will be further investigated using whole transcriptome analysis, RNA-seq, CRE-seq, and functional modeling. Aim 3: Communicate research results to enable translational research on new and rare Mendelian conditions - Disseminate: Our center is committed to data sharing and dissemination and will ensure that data is shared with the entire MGRC community through the data coordinating center. Through our industry partnership, clinically valid pipelines will be rapidly scaled for clinical implementation globally. Our overall approach provides an efficient and direct path to diagnosis for patients affected with undiagnosed Mendelian conditions, promotes gene discovery and reclassification of Variants of Uncertain Significance through a combination of innovative approaches, and will allow individuals, families and healthcare providers to improve the management of disease.

摘要